List of Excipients in Branded Drug RAMIPRIL

« Back to Dashboard

Generic Drugs Containing RAMIPRIL

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	ramipril	0054-0106	D&C YELLOW NO. 10
Hikma Pharmaceuticals USA Inc	ramipril	0054-0106	FD&C BLUE NO. 2
Hikma Pharmaceuticals USA Inc	ramipril	0054-0106	FD&C RED NO. 40
Hikma Pharmaceuticals USA Inc	ramipril	0054-0106	FD&C YELLOW NO. 6
Hikma Pharmaceuticals USA Inc	ramipril	0054-0106	FERROSOFERRIC OXIDE
Hikma Pharmaceuticals USA Inc	ramipril	0054-0106	GELATIN
Hikma Pharmaceuticals USA Inc	ramipril	0054-0106	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in RAMIPRIL?

# Of NDCs	Excipient
1	ACID YELLOW 3
1	ALCOHOL
1	AMMONIA
1	ANHYDROUS LACTOSE
3	BLUE 1
2	BUTYL ALCOHOL
2	CELLULOSE, MICROCRYSTALLINE

Ramipril Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Ramipril is an established small-molecule ACE inhibitor with expired originator exclusivity and a mature generic market. Commercial differentiation depends on bioequivalence execution, moisture and hydrolysis control, capsule presentation, fixed-dose combinations, supply reliability, and low-cost manufacturing rather than new-molecule patent protection. The strongest excipient strategy uses a simple, robust capsule or immediate-release tablet platform with tight control of water activity, excipient variability, and ramipril-to-ramiprilat degradation.

What is the FDA regulatory status of ramipril?

Ramipril is an FDA-approved oral ACE inhibitor marketed originally as Altace. Approved strengths include 1.25 mg, 2.5 mg, 5 mg, and 10 mg capsules. The drug is indicated for hypertension, reduction of cardiovascular risk in selected high-risk patients, and treatment after myocardial infarction in patients with clinical evidence of heart failure, subject to the applicable product labeling.[1]

Regulatory attribute	Ramipril status
Active ingredient	Ramipril
Drug class	Angiotensin-converting enzyme inhibitor
Original brand	Altace
Original sponsor	Monarch Pharmaceuticals, later associated with King Pharmaceuticals and sanofi-related commercial structures
Dosage form	Immediate-release oral capsule
Common strengths	1.25 mg, 2.5 mg, 5 mg, 10 mg
FDA pathway for competitors	ANDA generic approval
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
Therapeutic category	Hypertension, cardiovascular risk reduction, post-myocardial-infarction heart failure
Key regulatory issue	Demonstration of pharmaceutical equivalence and bioequivalence

Ramipril is a prodrug. It is hydrolyzed to ramiprilat, the active ACE-inhibiting metabolite. This conversion creates a formulation and analytical-control issue because excessive moisture, heat, or unsuitable processing conditions can increase degradation during manufacture or storage.[1]

When did ramipril lose exclusivity?

Ramipril’s original compound and regulatory exclusivity periods have expired. The commercial market is therefore driven by generic competition, contract manufacturing, supply agreements, and product differentiation.

The practical exclusivity profile is:

Exclusivity category	Commercial position
Original small-molecule patent protection	Expired
FDA new-drug exclusivity	Expired
Generic entry	Established
Paragraph IV opportunity	Primarily relevant to any later-listed formulation or method patents, not the original molecule
Biosimilar competition	Not applicable
Market access strategy	ANDA, authorized generic, private label, or licensed supply

The FDA Orange Book remains the controlling source for current listed patents and exclusivity entries. For a mature product such as ramipril, a new applicant’s principal risks are generally manufacturing, bioequivalence, quality, and commercial execution rather than infringement of an active basic-compound patent.[2]

What excipients are used in ramipril capsules?

Ramipril capsules generally use a low-complexity excipient system. The precise composition varies by manufacturer and dosage strength, but common excipient functions include filler, binder, disintegrant, lubricant or surfactant, capsule shell materials, and colorants.

Reference ramipril capsule labeling identifies excipient systems that can include pregelatinized starch, gelatin, titanium dioxide, sodium lauryl sulfate, and iron oxide colorants.[3] A generic applicant can use a different formulation if the product meets quality, pharmaceutical equivalence, and bioequivalence requirements.

Functional excipient map

Excipient function	Candidate materials	Ramipril relevance
Diluent and filler	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Supports low-dose content uniformity and capsule fill weight
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Improves granule or plug integrity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid capsule-content dispersion
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection and powder flow
Surfactant or wetting agent	Sodium lauryl sulfate, polysorbates in selected systems	Can improve wetting but may affect dissolution and stability
Moisture-control excipient	Low-moisture grades of standard fillers and disintegrants	Reduces hydrolytic degradation risk
Capsule shell	Gelatin or hypromellose	Enables capsule presentation and color differentiation
Colorant	Titanium dioxide, iron oxides, approved colorants	Supports strength identification and product recognition

For a conventional immediate-release capsule, the preferred development strategy is to minimize the number of excipients and avoid unnecessary formulation complexity. Each additional component increases extractables, supplier qualification, compatibility, and regulatory-control requirements.

Which excipient strategy is strongest for ramipril?

A robust ramipril formulation should prioritize four attributes: low moisture exposure, rapid and reproducible release, uniform low-dose distribution, and scalable manufacturing.

1. Low-moisture formulation design

Hydrolytic sensitivity is the primary excipient-screening concern. The development program should compare:

• Low-moisture microcrystalline cellulose.
• Pregelatinized starch with controlled water content.
• Anhydrous or low-water grades of selected fillers.
• Hypromellose capsule shells where gelatin moisture exchange creates risk.
• Desiccant-supported packaging for high-humidity markets.

The final formulation should be assessed using water activity, Karl Fischer water, impurity profiling, and accelerated stability. Total water content alone may not predict degradation as effectively as water activity and local moisture distribution.

2. Direct blending versus wet granulation

Direct blending is commercially attractive because it reduces processing steps and limits exposure to water and heat. It is suitable where the API and excipients have adequate flow, segregation resistance, and content-uniformity performance.

Wet granulation can improve blend uniformity and flow but introduces water and drying conditions that may accelerate ramipril degradation. It should be used only where direct blending fails critical quality attributes or where the manufacturing platform already has validated low-moisture granulation controls.

3. Capsule versus tablet

Capsules have several advantages:

• Alignment with the established Altace presentation.
• Simple immediate-release development.
• Easy strength differentiation through shell color.
• Lower compression-related development risk.
• Potentially shorter development timelines.

Tablets can reduce packaging cost and improve line efficiency, but they require control of compression force, capping, friability, disintegration, and dose uniformity. A tablet may be commercially attractive for high-volume supply, but it offers limited consumer differentiation in a commodity market.

4. Lubrication control

Excessive magnesium stearate can delay wetting and dissolution, particularly in a low-dose formulation with a high excipient-to-API ratio. Lubricant concentration, blending time, and shear should be established as critical process parameters.

Sodium stearyl fumarate may be considered where magnesium stearate produces dissolution or compatibility problems. Any lubricant substitution requires comparative dissolution and stability work because the product’s release profile can change without a visible physical difference.

What formulation patents could protect ramipril products?

The original ramipril molecule is no longer the principal source of patent value. Potentially protectable subject matter is more likely to involve:

• Stabilized ramipril compositions.
• Low-moisture capsule formulations.
• Solid dispersions or particle-engineered API.
• Modified-release dosage forms.
• Oral liquid formulations.
• Fixed-dose ramipril combinations.
• Pediatric formulations.
• Packaging systems that reduce moisture ingress.
• Manufacturing processes that improve assay uniformity or impurity control.
• Specific impurity limits or analytical-control processes, where legally eligible.

A formulation patent must provide more than a routine substitution of one conventional excipient for another. Commercially useful claims would need a defensible combination of composition, measurable performance, and manufacturing benefit. Examples could include a defined moisture range, impurity profile, dissolution window, or stability advantage tied to a specific excipient system.

Method-of-use patents have limited value for conventional hypertension treatment because the underlying clinical uses are old and widely practiced. More defensible method claims would need a narrowly defined patient population, dosing protocol, biomarker, combination regimen, or treatment sequence. Such claims would also face enforcement and prescribing-substitution challenges in a mature generic market.

How many patents cover ramipril?

The number of historical ramipril patents is materially larger than the number of commercially meaningful active patents. Original composition-of-matter and early formulation rights have expired. Current freedom-to-operate analysis should separate:

1. Expired basic-compound patents.
2. Expired originator formulation patents.
3. Any active jurisdiction-specific formulation or combination patents.
4. Manufacturing-process patents.
5. Packaging and device claims.
6. Third-party patents covering combination products.

The relevant patent estate is therefore fragmented rather than concentrated. A generic ramipril capsule usually has a lower patent barrier than newer cardiovascular products, but a company pursuing a differentiated liquid, modified-release, or fixed-dose product requires a separate patent search in the United States, Europe, Japan, China, and other target markets.

What commercial opportunities exist for ramipril?

The strongest opportunities are operational and formulation-based.

Generic capsule supply

Ramipril remains suitable for:

• ANDA-based generic launch.
• Regional generic registration.
• Private-label pharmacy supply.
• Hospital and government tenders.
• Contract manufacturing.
• Authorized-generic arrangements.
• Portfolio bundling with other cardiovascular drugs.

The base product is price-sensitive. A new entrant needs a cost advantage, a reliable API source, differentiated packaging, or access to a distribution channel.

Fixed-dose combinations

Potential combination opportunities include ramipril with:

• Hydrochlorothiazide.
• A calcium-channel blocker.
• A statin.
• Other cardiovascular agents where local regulation and clinical evidence support the product.

Combination products offer higher formulation value than standalone ramipril, but they also create more complex bioequivalence, stability, impurity, and patent-clearance requirements. Each active ingredient can introduce separate patent and regulatory issues.

Oral liquid and compounding products

An oral solution or suspension can address patients who cannot swallow capsules, including selected pediatric, geriatric, and enteral-feeding populations. The formulation challenge is substantial because ramipril hydrolysis, preservative compatibility, pH, container closure, and in-use stability must be controlled.

A liquid product is more defensible commercially than another standard capsule if it has:

• Demonstrated chemical stability.
• A practical shelf life.
• Reliable dose delivery.
• Low sedimentation or resuspendability risk.
• Compatibility with enteral tubes.
• Packaging that limits moisture and oxygen exposure.

Low-cost global supply

Emerging markets may offer volume opportunities for manufacturers with:

• Stable API procurement.
• Local regulatory registrations.
• Humidity-resistant packaging.
• Multi-strength production.
• Tender-compliant pricing.
• Regional pharmacovigilance and serialization capability.

The primary barrier is often not patent ownership. It is product registration, quality consistency, and price competition from established suppliers.

What manufacturing and IP barriers affect ramipril?

API and impurity control

Ramipril manufacturing requires control of related substances, residual solvents, water content, and degradation products. The conversion of ramipril to ramiprilat must be monitored during API storage, formulation, and finished-product stability studies.

Supplier qualification

A commercial formulation should not depend on a single excipient supplier unless the excipient is tightly specified and dual sourcing is impractical. Changes in starch, cellulose, gelatin, or capsule-shell grades can affect dissolution, fill weight, moisture, and stability.

Packaging

Alu-Alu blister packaging can provide stronger moisture protection than conventional high-density polyethylene bottles, although it can increase unit cost. For bottles, induction seals, desiccants, low-permeability containers, and controlled headspace may be required.

Packaging can create a modest commercial barrier even when it does not support a strong standalone patent position. A competitor may reproduce the formulation but fail to match shelf life or stability in high-humidity regions.

Process know-how

Important manufacturing know-how can include:

• Order of excipient addition.
• Blend time and shear.
• Lubrication endpoint.
• Capsule-filling controls.
• Environmental humidity limits.
• In-process water-activity limits.
• API particle-size specifications.
• Packaging line controls.

These measures may be protected as trade secrets rather than patents.

What is the Paragraph IV risk for ramipril?

For standard ramipril capsules, Paragraph IV risk is generally limited because the originator’s principal exclusivity has expired and generic products are already established. Paragraph IV activity becomes more relevant when a company develops:

• A new oral liquid.
• A modified-release product.
• A fixed-dose combination.
• A pediatric dosage form.
• A formulation relying on an active third-party patent.
• A product that challenges a later-listed formulation or method patent.

The applicant should conduct a complete Orange Book and global patent review before filing. A Paragraph IV strategy can accelerate market entry where an active patent remains, but it introduces litigation cost, launch-at-risk exposure, and potential damages.

What patent litigation and settlements affect ramipril?

Ramipril does not have the litigation profile associated with newer high-value branded cardiovascular drugs. The principal commercial disputes are more likely to involve:

• ANDA certification and listed patents.
• Fixed-dose combination products.
• Process patents.
• Regulatory exclusivity disputes.
• Supply agreements and API quality.
• Trademark or trade-dress issues.

Settlement value is limited for a mature standalone capsule unless the challenged product has a differentiated formulation or a substantial distribution advantage. A license may still be commercially useful where it provides access to a formulation, regional registration, validated manufacturing process, or reliable API source.

How does ramipril compare with other ACE inhibitors?

Drug	Generic maturity	Formulation opportunity	Patent barrier	Commercial differentiation
Ramipril	High	Moisture-controlled capsule, liquid, combinations	Low for basic capsule	Stability, supply, combinations
Enalapril	High	Tablet, oral solution, combinations	Low for basic product	Pediatric and liquid formats
Lisinopril	High	Tablet, solution, orally disintegrating formats	Low for basic product	Cost and dosage-form convenience
Perindopril	High in many markets	Salt and combination products	Jurisdiction-dependent	Combination products
Captopril	High	Stability-sensitive tablet and liquid products	Low for basic product	Packaging and shelf life
Benazepril	High	Capsule and combination products	Low for basic product	Portfolio and channel access

Ramipril has a stronger formulation rationale than some ACE inhibitors because hydrolysis and moisture management can affect product quality. That does not create automatic patent value, but it can support a differentiated development program.

What is the revenue exposure for ramipril products?

Revenue exposure is concentrated in high-volume, low-price generic sales. A standalone ramipril capsule generally has limited pricing power. The most attractive commercial models are:

1. Multi-strength supply contracts.
2. Fixed-dose cardiovascular combinations.
3. Private-label distribution.
4. Regional tenders.
5. Contract manufacturing with validated stability data.
6. Pediatric or geriatric liquid products.
7. High-humidity market packaging.
8. Portfolio sales paired with other antihypertensives.

A company should model volume, net price, tender erosion, API cost, packaging cost, and regulatory maintenance separately. Gross margin can deteriorate quickly if the product depends on premium packaging without a corresponding reimbursement or channel advantage.

How strong is the ramipril patent estate?

The basic ramipril patent estate is weak from a new-entry perspective because the original compound and core commercial product have been generic for many years. The remaining opportunity is selective patenting around:

• New dosage forms.
• Defined stability advantages.
• Combination products.
• Patient-specific administration methods.
• Manufacturing controls.
• Packaging systems.

The strongest strategy is layered protection. A company should combine composition claims with process know-how, regulatory data, trademarks, supply agreements, and channel contracts. A formulation patent alone is unlikely to create durable market exclusivity for a low-price ACE inhibitor.

What generic launch scenarios exist for ramipril?

Scenario 1: Standard capsule launch

This is the fastest and lowest-risk route. The product competes primarily on price, supply reliability, and registration coverage.

Scenario 2: Stabilized capsule

A low-moisture formulation with improved accelerated stability can support a packaging or formulation differentiation strategy. Regulatory benefit depends on demonstrated product performance.

Scenario 3: Pediatric or geriatric liquid

This route offers greater unmet-use differentiation but requires more extensive stability, dosing, container, and in-use studies.

Scenario 4: Fixed-dose combination

This can improve commercial positioning but has greater regulatory and patent complexity.

Scenario 5: Regional licensing

A manufacturer with an approved product can license registrations, trademarks, or supply rights to distributors in markets where it lacks sales infrastructure.

Key Takeaways

• Ramipril is an established generic small molecule with expired original exclusivity.
• The commercial opportunity is formulation-led, not compound-patent-led.
• Moisture and hydrolysis control should drive excipient selection and packaging design.
• Pregelatinized starch, microcrystalline cellulose, controlled-moisture excipients, disintegrants, and suitable capsule shells are practical development options.
• Direct blending is attractive when it meets content-uniformity and flow requirements without introducing water.
• Standard capsules are low-risk but highly price-sensitive.
• Oral liquids and fixed-dose combinations offer stronger differentiation but require more extensive development.
• Biosimilar competition is irrelevant because ramipril is not a biologic.
• Paragraph IV exposure is limited for standard capsules but can reappear around later-listed formulations and combinations.
• Trade secrets, supply reliability, packaging, and regulatory execution may create more value than a standalone formulation patent.
• The strongest commercial model combines multi-strength supply with a differentiated formulation or cardiovascular combination portfolio.

FAQs

Is ramipril a good candidate for an oral liquid?

Yes. An oral liquid can address swallowing and enteral-administration needs, but hydrolysis, pH, preservative compatibility, in-use stability, and container closure are central development risks.

Which packaging is best for ramipril stability?

High-barrier blister packaging, particularly Alu-Alu systems, can provide strong moisture protection. Bottles may be suitable when combined with a tight closure, induction seal, desiccant, and validated stability data.

Can a company patent a new ramipril excipient combination?

Possibly, if the formulation provides a non-obvious and measurable technical benefit, such as improved stability, dissolution, impurity control, or shelf life. Routine excipient substitution is less likely to support durable patent protection.

Does ramipril require a biosimilar application?

No. Ramipril is a chemically synthesized small molecule. Competitors generally use the generic ANDA pathway in the United States rather than the biosimilar pathway.

Are ramipril fixed-dose combinations more attractive than standalone capsules?

They can be. Combinations may provide stronger clinical and commercial differentiation, but they require additional bioequivalence work, stability testing, patent review, labeling analysis, and manufacturing controls.

References

1. U.S. Food and Drug Administration. (2018). Altace (ramipril) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
3. DailyMed. (2024). Ramipril capsule labeling. National Library of Medicine.
4. U.S. Food and Drug Administration. (2024). ANDA approvals and generic drug information. FDA.